Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but frequency of IOP spikes above 30 mm Hg did not increase, according to a study.
Researchers evaluated a total of 183 Ozurdex (dexamethasone intravitreal implant, Allergan) injections of either 0.7 mg or 0.35 mg over a period of at least 12 months in 171 patients. A total of 139 eyes received a single injection, 25 eyes received two injections, and 19 eyes received three injections.
Repeated injections increased the frequency of mild (23 mm Hg) and moderate (25 mm Hg) IOP spikes, but not severe spikes of 30 mm Hg or greater.
“Therefore, if a patient did not have an IOP spike of above 30 mm Hg after a single implant of Ozurdex, it is unlikely that subsequent implants cause such an IOP spike,” the researchers wrote.
Patients with primary open angle glaucoma had significantly greater mean IOP spikes (25.1 mm Hg) than patients with no medical or family history of glaucoma (20.8 mm Hg) after a single injection (P = .004); the researchers suggested that these patients be monitored carefully.
Patients with uveitis had the greatest mean IOP spike (24.3 mm Hg) compared with patients with central retinal vein occlusion (21.8 mm Hg), branch retinal vein occlusion (21.1 mm Hg) and (20.7 mm Hg) after a single injection. – by Robert Linnehan
Disclosures: Bahadorani reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.